^
    4years
    Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1) (clinicaltrials.gov)
    P1/2, N=162, Not yet recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Clinical • New P1/2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • DZD3969